RT Journal Article
SR Electronic
T1 Mapping the emergence of SARS-CoV-2 Omicron variants on a university campus
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.04.27.22274375
DO 10.1101/2022.04.27.22274375
A1 Weil, Ana A.
A1 Luiten, Kyle G.
A1 Casto, Amanda M.
A1 Bennett, Julia C.
A1 O’Hanlon, Jessica
A1 Han, Peter D.
A1 Gamboa, Luis
A1 McDermot, Evan
A1 Truong, Melissa
A1 Gottlieb, Geoffrey S.
A1 Acker, Zack
A1 Wolf, Caitlin R.
A1 Magedson, Ariana
A1 Chow, Eric J.
A1 Lo, Natalie K.
A1 Pothan, Lincoln C.
A1 McDonald, Devon
A1 Wright, Tessa
A1 McCaffrey, Kathryn
A1 Figgins, Marlin D.
A1 Englund, Janet A.
A1 Boeckh, Michael
A1 Lockwood, Christina M.
A1 Nickerson, Deborah A.
A1 Shendure, Jay
A1 Bedford, Trevor
A1 Hughes, James P.
A1 Starita, Lea M.
A1 Chu, Helen Y.
YR 2022
UL http://medrxiv.org/content/early/2022/04/28/2022.04.27.22274375.abstract
AB Novel variants continue to emerge in the SARS-CoV-2 pandemic. University testing programs may provide timely epidemiologic and genomic surveillance data to inform public health responses. We conducted testing from September 2021 to February 2022 in a university population under vaccination and indoor mask mandates. A total of 3,048 of 24,393 individuals tested positive for SARS-CoV-2 by RT-PCR; whole genome sequencing identified 209 Delta and 1,730 Omicron genomes of the 1,939 total sequenced. Compared to Delta, Omicron had a shorter median serial interval between genetically identical, symptomatic infections within households (2 versus 6 days, P=0.021). Omicron also demonstrated a greater peak reproductive number (2.4 versus 1.8) and a 1.07 (95% confidence interval: 0.58, 1.57; P<0.0001) higher mean cycle threshold value. Despite near universal vaccination and stringent mitigation measures, Omicron rapidly displaced the Delta variant to become the predominant viral strain and led to a surge in cases in a university population.Competing Interest StatementHYC reports consulting with Ellume, Pfizer, The Bill and Melinda Gates Foundation, Glaxo Smith Kline, and Merck. HYC received research funding from Gates Ventures, Sanofi Pasteur, and support and reagents from Ellume and Cepheid outside of the submitted work. GSG received research grants and research support from the US National Institutes of Health, the University of Washington, the Bill & Melinda Gates Foundation, Gilead Sciences, Alere Technologies, Merck & Co., Janssen Pharmaceutica, Cerus Corporation, ViiV Healthcare, Bristol-Myers Squibb, Roche Molecular Systems, Abbott Molecular Diagnostics, and THERA Technologies/TaiMed Biologics, Inc, all outside of the submitted work. JAE reports research support from Gates Ventures, AstraZeneca, GlaxoSmithKline, Merck, and Pfizer, and consulting with Sanofi Pasteur, AstraZeneca, Teva Pharmaceuticals, and Meissa Vaccines, outside of the submitted work. MB reports research support from Vir Biotechnology, GSK, Regeneron, Gilead Sciences, Janssen Pharmaceutica, Ridgeback, Merck, Gates Ventures, and consulting with Vir Biotechnology, Moderna, Helocyte, and Merck outside of the submitted work.Funding StatementTesting for this study was funded by the CARES act.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB of University of Washington gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesParticipants of this study did not agree for their data to be shared publicly, and so supporting data is not available.